Regeneron

Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

Published: December 4, 2025 Key Takeaways Wall Street Re‑rates Regeneron After Big Run — and Bigger Dupixent Story Regeneron Pharmaceuticals has suddenly become one of the most hotly debated large‑cap biotechs on Wall Street. On Thursday, December 4, 2025, multiple

4 December 2025

Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is ending 2025 in full “complex biotech” mode: the share price has rebounded, the dividend is now real, a flagship drug just got a powerful new label, a rare-disease medicine crushed a Phase 3 trial,

3 December 2025

Company News · Gene Editing · Investment Analysis · NASDAQ:REGN · Pharmaceuticals · Stock Market

Regeneron (REGN) Stock on December 2, 2025: Outlook, Forecast and Key Catalysts After Gene‑Editing Deal

Regeneron stock snapshot on 2 December 2025 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is trading around $742 per share in late U.S. trading on December 2, 2025, after moving between roughly $731 and $749 during the session and opening close to

2 December 2025

Biotech Industry · Financial Forecast · Gene Editing · Investment Analysis · NASDAQ:REGN · Stock Market

Regeneron Stock Rockets on Strong Q3, Dupixent Boom – Analysts See 27% Upside

Key points: Regeneron (NASDAQ: REGN) shares recently traded around $580–$585 (closing at $585.31 on Oct 27) after a slight pullback earlier in the month investing.com. Over the past week REGN is up roughly 1–2%, recovering from a low in the

28 October 2025

Earnings Reports · Healthcare Industry · Investment Analysis · NASDAQ:REGN · Pharmaceuticals · Stock Market